209 related articles for article (PubMed ID: 9139722)
1. Proteinase specificity and functional diversity in point mutants of plasminogen activator inhibitor 1.
Gils A; Declerck PJ
J Biol Chem; 1997 May; 272(19):12662-6. PubMed ID: 9139722
[TBL] [Abstract][Full Text] [Related]
2. Conversion of plasminogen activator inhibitor-1 from inhibitor to substrate by point mutations in the reactive-site loop.
Audenaert AM; Knockaert I; Collen D; Declerck PJ
J Biol Chem; 1994 Jul; 269(30):19559-64. PubMed ID: 8034724
[TBL] [Abstract][Full Text] [Related]
3. Substrate behavior of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop.
Gils A; Knockaert I; Declerck PJ
Biochemistry; 1996 Jun; 35(23):7474-81. PubMed ID: 8652525
[TBL] [Abstract][Full Text] [Related]
4. Comparative analysis of the proteinase specificity in wild-type and stabilized plasminogen activator inhibitor-1: evidence for contribution of intramolecular flexibility.
De Taeye B; Gils A; Vleugels N; Rabijns A; Declerck PJ
Biochem Biophys Res Commun; 2004 Aug; 321(3):746-51. PubMed ID: 15358169
[TBL] [Abstract][Full Text] [Related]
5. Characterization of plasminogen activator inhibitor 1 mutants containing the P13 to P10 region of ovalbumin or antithrombin III: evidence that the P13 residue contributes significantly to the active to substrate transition.
Gils A; Vleugels N; Tobback K; Knockaert I; Declerck PJ
Biochim Biophys Acta; 1998 Sep; 1387(1-2):291-7. PubMed ID: 9748634
[TBL] [Abstract][Full Text] [Related]
6. Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms.
Debrock S; Declerck PJ
Biochim Biophys Acta; 1997 Feb; 1337(2):257-66. PubMed ID: 9048903
[TBL] [Abstract][Full Text] [Related]
7. Type-1 plasminogen-activator inhibitor -- conformational differences between latent, active, reactive-centre-cleaved and plasminogen-activator-complexed forms, as probed by proteolytic susceptibility.
Egelund R; Schousboe SL; Sottrup-Jensen L; Rodenburg KW; Andreasen PA
Eur J Biochem; 1997 Sep; 248(3):775-85. PubMed ID: 9342229
[TBL] [Abstract][Full Text] [Related]
8. Identification of positively charged residues contributing to the stability of plasminogen activator inhibitor 1.
Gils A; Lu J; Aertgeerts K; Knockaert I; Declerck PJ
FEBS Lett; 1997 Sep; 415(2):192-5. PubMed ID: 9350994
[TBL] [Abstract][Full Text] [Related]
9. Conformational changes of the reactive-centre loop and beta-strand 5A accompany temperature-dependent inhibitor-substrate transition of plasminogen-activator inhibitor 1.
Kjøller L; Martensen PM; Sottrup-Jensen L; Justesen J; Rodenburg KW; Andreasen PA
Eur J Biochem; 1996 Oct; 241(1):38-46. PubMed ID: 8898886
[TBL] [Abstract][Full Text] [Related]
10. The importance of helix F in plasminogen activator inhibitor-1.
Vleugels N; Gils A; Bijnens AP; Knockaert I; Declerck PJ
Biochim Biophys Acta; 2000 Jan; 1476(1):20-6. PubMed ID: 10606763
[TBL] [Abstract][Full Text] [Related]
11. Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a noninhibitory substrate for tissue-type plasminogen activator.
Declerck PJ; De Mol M; Vaughan DE; Collen D
J Biol Chem; 1992 Jun; 267(17):11693-6. PubMed ID: 1601844
[TBL] [Abstract][Full Text] [Related]
12. Resolution of Michaelis complex, acylation, and conformational change steps in the reactions of the serpin, plasminogen activator inhibitor-1, with tissue plasminogen activator and trypsin.
Olson ST; Swanson R; Day D; Verhamme I; Kvassman J; Shore JD
Biochemistry; 2001 Oct; 40(39):11742-56. PubMed ID: 11570875
[TBL] [Abstract][Full Text] [Related]
13. Engineering plasminogen activator inhibitor 1 mutants with increased functional stability.
Lawrence DA; Olson ST; Palaniappan S; Ginsburg D
Biochemistry; 1994 Mar; 33(12):3643-8. PubMed ID: 8142362
[TBL] [Abstract][Full Text] [Related]
14. Distal hinge of plasminogen activator inhibitor-1 involves its latency transition and specificities toward serine proteases.
Wang Q; Shaltiel S
BMC Biochem; 2003 Jul; 4():5. PubMed ID: 12848892
[TBL] [Abstract][Full Text] [Related]
15. Immobilization of the distal hinge in the labile serpin plasminogen activator inhibitor 1: identification of a transition state with distinct conformational and functional properties.
De Taeye B; Compernolle G; Dewilde M; Biesemans W; Declerck PJ
J Biol Chem; 2003 Jun; 278(26):23899-905. PubMed ID: 12686544
[TBL] [Abstract][Full Text] [Related]
16. A concerted structural transition in the plasminogen activator inhibitor-1 mechanism of inhibition.
Blouse GE; Perron MJ; Thompson JH; Day DE; Link CA; Shore JD
Biochemistry; 2002 Oct; 41(40):11997-2009. PubMed ID: 12356300
[TBL] [Abstract][Full Text] [Related]
17. Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries.
Stoop AA; Eldering E; Dafforn TR; Read RJ; Pannekoek H
J Mol Biol; 2001 Jan; 305(4):773-83. PubMed ID: 11162091
[TBL] [Abstract][Full Text] [Related]
18. Rational design of complex formation between plasminogen activator inhibitor-1 and its target proteinases.
Aertgeerts K; De Ranter CJ; Booth NA; Declerck PJ
J Struct Biol; 1997 Apr; 118(3):236-42. PubMed ID: 9169233
[TBL] [Abstract][Full Text] [Related]
19. A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis.
Chorostowska-Wynimko J; Swiercz R; Skrzypczak-Jankun E; Wojtowicz A; Selman SH; Jankun J
Mol Cancer Ther; 2003 Jan; 2(1):19-28. PubMed ID: 12533669
[TBL] [Abstract][Full Text] [Related]
20. A serpin-induced extensive proteolytic susceptibility of urokinase-type plasminogen activator implicates distortion of the proteinase substrate-binding pocket and oxyanion hole in the serpin inhibitory mechanism.
Egelund R; Petersen TE; Andreasen PA
Eur J Biochem; 2001 Feb; 268(3):673-85. PubMed ID: 11168406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
